Quercetin Side Effects: Kidney Caution and Interactions
Informational summary of published research — not medical advice. Quercetin has real interactions with quinolone antibiotics and possibly other medications; if you take any prescription drug or have kidney disease, check with a doctor or pharmacist before starting quercetin. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Short-term oral quercetin, up to roughly 1,000-2,000mg/day, is well tolerated in the trials that have tested it directly — no drug-related severe adverse effects distinguishable from placebo in trials running one to four weeks. The kidney-injury fear you may have heard about is real, but it comes from intravenous quercetin given at cancer-trial doses far beyond anything an oral capsule delivers — that is a different exposure, not a warning about the supplement on a shelf. The genuine cautions for an oral supplement are a quinolone-antibiotic interaction (quercetin competes for the same bacterial target and may blunt the antibiotic), a CYP3A4 drug-interaction question that matters for cyclosporine, statins, and similar medications, and the fact that enhanced-absorption forms (phytosome, EMIQ) deliver more quercetin per labeled mg, so a dose that's fine as plain quercetin isn't automatically fine at the same mg number in those forms.
Looking for a tested product? See our best quercetin ranked separately by form and cost per mg, since plain and phytosome are not the same dose →
Short-term oral tolerability: what the trials that tested it directly found
The most direct evidence on tolerability comes from trials designed to test it. A dose-escalation safety study in patients with COPD (Han 2020) tested oral quercetin at 500, 1,000, and then 2,000mg/day over one week and found it safely tolerated, with no study-drug-related severe adverse events based on lung function, complete blood counts, or a comprehensive metabolic panel. A 28-day trial in healthy adults (Conquer 1998) at 1,000mg/day reported no adverse changes on the cardiovascular and metabolic markers it measured. A dedicated safety review of the published human intervention literature (Andres 2018) summarizes the pattern across studies: adverse effects following supplemental quercetin intake have been rarely reported, and any such effects were mild in nature.
The gap worth being honest about: none of this is long-term data. Andres 2018 is explicit that adequate safety data for high supplemental doses (1,000mg/day and up) used for longer than about 12 weeks simply doesn't exist yet. "Well tolerated in the trials so far" and "proven safe indefinitely at high doses" are different claims, and only the first one is supported.
The kidney caution — and why intravenous quercetin is not the same story as an oral capsule
The nephrotoxicity reports that circulate about quercetin come from intravenous cancer-trial doses, not oral supplementation. A Phase I clinical trial of intravenous quercetin in cancer patients (Ferry 1996) used IV bolus doses of 945–1,700 mg/m² and found dose-limiting nephrotoxicity: at 1,400 mg/m², 2 of 10 evaluable patients had renal toxicity (one grade 2, one grade 4); at 945 mg/m², 3 of 14 patients had clinically significant renal toxicity. Even at the recommended weekly dose, patients showed an average 19% fall in glomerular filtration rate in the 24 hours after each infusion. Those are IV doses that bypass digestion and first-pass metabolism entirely — they put far more quercetin directly into the bloodstream than any oral capsule can, so this trial is not evidence that an oral supplement causes kidney injury.
What does carry over to oral use is a narrower, theoretical caution: based on animal studies, quercetin has the potential to worsen nephrotoxic effects specifically in an already-damaged kidney (Andres 2018). That's a reason for people with pre-existing kidney disease to talk to a doctor before supplementing at high doses, not a demonstrated risk for someone with normal kidney function taking a standard oral dose. No human oral trial — including the 1,000–2,000mg/day trials above — has reported kidney injury.
Quinolone antibiotics: a real interaction, and it may work against the antibiotic
Quinolone antibiotics — ciprofloxacin, levofloxacin, and related drugs — work by binding to bacterial DNA gyrase and blocking it. A structural pharmacology study (Hilliard 1995) found that flavone compounds, quercetin among them, can bind at or near that same active site on DNA gyrase. That overlap means quercetin taken alongside a quinolone antibiotic could compete with the drug for its own bacterial target — a mechanism that, if it plays out in the body the way it does in binding studies, would blunt the antibiotic rather than add anything useful to it. This is a mechanistic/binding-site finding rather than a clinical trial measuring infection outcomes, but the direction of the concern (interference, not synergy) is different from most supplement-drug interaction warnings, which is why it's worth taking seriously. If you're prescribed a quinolone antibiotic, the simplest approach is to pause quercetin supplementation until the course is finished, or check with a pharmacist first.
CYP3A4 and cyclosporine-class drugs — real modulation, unpredictable direction
Quercetin measurably inhibits CYP3A4 — the liver and intestinal enzyme responsible for clearing cyclosporine, many statins, and a long list of other narrow-therapeutic-window drugs. In human liver and intestinal microsomes, quercetin inhibited CYP3A4-mediated metabolism of a model drug substrate (Fasinu 2013), the kind of finding usually cited as reason to expect quercetin will raise blood levels of CYP3A4-cleared drugs.
But the one study that actually measured quercetin's effect on a real CYP3A4 substrate drug in a living system found the opposite direction. Repeated quercetin dosing in rats lowered cyclosporine's blood levels — peak concentration fell 46–50% and total exposure (AUC) fell 16–34% — through a combined effect on intestinal and hepatic drug-metabolizing enzymes and transporters, not simple enzyme inhibition (Liu 2016). No human pharmacokinetic trial has tested quercetin against cyclosporine or a comparable CYP3A4-cleared drug directly, so which direction this goes in a person — higher drug levels, lower drug levels, or both depending on timing and dose — is not something the current evidence can predict. That unpredictability is itself the reason for caution: if you take cyclosporine, a statin, or any other CYP3A4-metabolized medication with a narrow safety margin, don't assume quercetin is neutral, and check with a doctor or pharmacist before combining them.
Enhanced-absorption forms change the exposure a "safe dose" number is based on
Every dose figure above — the 1,000–2,000mg/day tolerated in Han 2020 and Conquer 1998, the "rarely reported, mild" pattern in Andres 2018 — was established using plain (unformulated) quercetin dihydrate. Phytosome quercetin (lecithin-bound, branded Quercefit) is a different exposure at the same label number: a randomized crossover pharmacokinetic trial (Riva 2019) found it reaches plasma concentrations up to 20 times higher than plain quercetin at an identical labeled mg dose. Enzymatically modified isoquercitrin (EMIQ), engineered with a different chemistry, similarly reaches substantially higher blood concentrations than unmodified quercetin (Owczarek-Januszkiewicz 2022).
Neither enhanced-absorption form has its own dedicated long-term safety trial at the doses now sold commercially — the tolerability data above is plain-quercetin data. A "1,000mg is well tolerated" conclusion, applied uncritically to a phytosome or EMIQ product labeled the same 1,000mg, is comparing a known short-term safety record to an unmeasured, higher actual exposure. See the dosage guide for how the trial doses map to each form.
Quercetin side effects at a glance
| Concern | What the evidence shows | Route / form it applies to | When it matters |
|---|---|---|---|
| General short-term tolerability | Well tolerated up to 1,000–2,000mg/day in trials of 1–4 weeks; no severe drug-related effects reported | Oral, plain quercetin | Baseline expectation for most healthy adults |
| Kidney injury (nephrotoxicity) | Dose-limiting in a Phase I trial of IV bolus doses (945–1,700mg/m²); a theoretical caution only in a pre-damaged kidney with oral use | Intravenous (cancer-trial doses) ≠ oral supplement | Pre-existing kidney disease (oral); not applicable to a supplement capsule at any studied dose |
| Quinolone antibiotic interaction | Quercetin can bind the same DNA-gyrase active site quinolones target — may blunt the antibiotic | Oral, any form, taken with ciprofloxacin/levofloxacin/etc. | Anyone prescribed a quinolone antibiotic |
| CYP3A4 / cyclosporine-class interaction | Inhibits CYP3A4 in vitro; the one in vivo (rat) cyclosporine study found decreased, not increased, drug exposure — direction unpredictable in humans | Oral, any form | Anyone on cyclosporine, statins, or other CYP3A4-metabolized drugs with a narrow safety margin |
| Higher exposure per label mg | Phytosome reaches up to 20× higher plasma levels than plain at the same mg; EMIQ similarly enhanced | Phytosome (Quercefit) and EMIQ specifically | Anyone assuming a plain-quercetin "safe dose" transfers directly to an enhanced-absorption label |
| Long-term high-dose safety | No human trial has studied doses ≥1,000mg/day for longer than about 12 weeks | Oral, any form | Anyone planning ongoing daily use above 1,000mg/day |
Verified Quercetin Products, Ranked by Form and Cost Per Mg
If you're ready to buy, here's how the quercetin products we track and verify compare — ranked separately by form since plain and phytosome are not dose-equivalent.
| Product | Dose/Serving | Servings | Price | Cost/Day | Certification | Buy |
|---|---|---|---|---|---|---|
| Doctor's Best Quercetin Bromelain | 500mg quercetin | 180 | $29.99 | $0.17 | None claimed | Buy on Amazon |
| Jarrow Formulas Quercetin 500 mg | 500mg quercetin | 200 | $52.94 | $0.26 | None claimed | Buy on Amazon |
| Nutricost Quercetin 1000 mg | 1000mg quercetin | 60 | $19.95 | $0.33 | None claimed | Buy on Amazon |
| NOW Foods Quercetin with Bromelain | 800mg quercetin | 60 | $23.34 | $0.40 | None claimed | Buy on Amazon |
| Quercetin Complete (Quercefit Phytosome + Bromelain, Zinc, Vitamin C) | 500mg quercetin (phytosome) | 60 | $26.99 | $0.45 | None claimed | Buy on Amazon |
| Thorne Quercetin Phytosome | 250mg quercetin (phytosome) | 60 | $46.00 | $0.77 | None independently confirmed on this fetch (Thorne brand-level manufacturing standards) | Buy on Amazon |
Frequently asked questions
Is quercetin safe? What are the most common side effects?
Short-term oral quercetin is well tolerated in the human trials that have specifically tested it. A dose-escalation safety trial in COPD patients (Han 2020) found doses up to 2,000mg/day safely tolerated over one week, with no drug-related severe adverse events on blood work or lung function. A 28-day trial at 1,000mg/day in healthy adults (Conquer 1998) reported no adverse effects distinguishable from baseline. A broader safety review of published human intervention studies (Andres 2018) describes adverse effects following supplemental quercetin as rarely reported and mild when they occur. The important gap: no human trial has tested high-dose oral quercetin (1,000mg/day or more) for longer than about 12 weeks, so long-term safety at high doses is genuinely unknown, not just unstudied in passing.
I've heard quercetin can hurt your kidneys — is that true?
It depends entirely on the route and the dose, and the two get conflated constantly. The kidney injury reports come from intravenous quercetin given at cancer-trial doses — a Phase I trial (Ferry 1996) using IV bolus doses of 945-1,700mg/m² found dose-limiting nephrotoxicity, including a measurable fall in glomerular filtration rate after dosing and grade 2-4 renal toxicity in some patients at the higher doses tested. That is a different substance exposure entirely from an oral supplement capsule: those IV doses bypass absorption and first-pass metabolism completely, delivering blood concentrations an oral dose cannot reach. Separately, animal studies have identified a theoretical concern that oral quercetin could worsen nephrotoxic effects specifically in an already-damaged kidney (Andres 2018) — a reason for caution if you have pre-existing kidney disease, not evidence that oral quercetin harms healthy kidneys. No oral human trial has reported kidney injury at the doses sold as supplements.
Does quercetin interact with antibiotics?
Yes — with quinolone antibiotics specifically (ciprofloxacin, levofloxacin, and related drugs), and the mechanism is structural, not metabolic. Quinolone antibiotics work by binding to bacterial DNA gyrase. Quercetin, structurally, is also able to bind at or near that same active site (Hilliard 1995) — so taking the two together may mean quercetin competes with the antibiotic for its bacterial target, a mechanism that could blunt the antibiotic's effectiveness rather than add to its action. This is a binding-site/mechanistic finding, not a clinical outcomes trial, but it's a real enough concern that the sensible approach is to avoid taking quercetin supplements while on a course of quinolone antibiotics, or at minimum separate the doses and check with a pharmacist first.
Does quercetin affect how other drugs are metabolized (CYP3A4)?
Yes, and the honest answer is that quercetin is a real CYP3A4 modulator but the net effect on a specific drug isn't reliably predictable from that fact alone. In human liver and intestinal microsomes, quercetin measurably inhibits CYP3A4-mediated metabolism of a model drug (Fasinu 2013) — the enzyme that clears cyclosporine, many statins, and other narrow-therapeutic-window medications. But the one whole-animal pharmacokinetic study using an actual CYP3A4 substrate drug, cyclosporine, found the opposite direction of effect in practice: repeated quercetin dosing in rats lowered, not raised, cyclosporine's blood levels (by roughly 16-34% AUC), through a combined effect on metabolizing enzymes and drug transporters (Liu 2016). No human pharmacokinetic trial has tested quercetin against cyclosporine or a similar CYP3A4-cleared drug directly. The practical takeaway is caution, not a predicted direction: if you take cyclosporine, a statin, or any other CYP3A4-metabolized medication with a narrow safety margin, talk to a doctor or pharmacist before adding quercetin rather than assuming it will simply raise or lower your drug levels.
Does a 'safe dose' established for plain quercetin apply to phytosome or EMIQ formulas too?
No, and this is the detail most side-effect discussions skip. The oral safety data described above — doses up to 1,000-2,000mg/day tolerated over one to twelve weeks — was measured using plain (unformulated) quercetin dihydrate. Enhanced-absorption formulations reach meaningfully higher blood levels at the same labeled milligram amount: a randomized crossover trial (Riva 2019) found phytosome quercetin (Quercefit) reached plasma concentrations up to 20 times higher than plain quercetin at an identical mg dose. Enzymatically modified isoquercitrin (EMIQ), a separate high-absorption form, works through different chemistry to the same end (Owczarek-Januszkiewicz 2022) but similarly increases how much of the labeled dose actually reaches your bloodstream. Neither form has its own dedicated long-term human safety trial at the doses now sold commercially. A "1,000mg is fine" conclusion drawn from plain-quercetin tolerability data does not automatically transfer to a phytosome or EMIQ label claiming the same milligram number — the actual systemic exposure is higher.
Related guides
- Quercetin Dosage Guide — Plain vs. phytosome dosing, with a dose checker
- Quercetin Benefits — What the trials actually support, graded by evidence strength
- Does Quercetin Work? — The complete evidence verdict, including allergies and exercise claims
- Best Quercetin — Verified picks, ranked separately by form and cost per mg
- All Quercetin Guides
Sources
- Han MK, et al. "Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease." BMJ Open Respir Res. 2020 Feb. PMID: 32071149
- Conquer JA, et al. "Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects." J Nutr. 1998. PMID: 9482769
- Andres S, Pevny S, et al. "Safety Aspects of the Use of Quercetin as a Dietary Supplement." Mol Nutr Food Res. 2018 Jan. PMID: 29127724
- Ferry DR, et al. "Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition." Clin Cancer Res. 1996 Apr. PMID: 9816216 (intravenous dosing, cancer trial — not oral supplementation).
- Hilliard JJ, Krause HM, et al. "A comparison of active site binding of 4-quinolones and novel flavone gyrase inhibitors to DNA gyrase." Adv Exp Med Biol. 1995. PMID: 8718602
- Fasinu PS, et al. "Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability." J Pharm Sci. 2013 Feb. PMID: 23188647
- Liu Y, et al. "Impact of quercetin-induced changes in drug-metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats." Mol Med Rep. 2016 Oct. PMID: 27510982 (rat study).
- Riva A, Ronchi M, et al. "Improved Oral Absorption of Quercetin from Quercetin Phytosome®, a New Delivery System Based on Food Grade Lecithin." Eur J Drug Metab Pharmacokinet. 2019 Apr. PMID: 30328058
- Owczarek-Januszkiewicz A, Magiera A, et al. "Enzymatically Modified Isoquercitrin: Production, Metabolism, Bioavailability, Toxicity, Pharmacology, and Related Molecular Mechanisms." Int J Mol Sci. 2022 Nov. PMID: 36499113